Over the last eight years, fatal overdoses linked to fentanyl combined with stimulants like cocaine and methamphetamine have skyrocketed among individuals aged 65 and above, marking a staggering 9,000% increase. This alarming trend now aligns closely with overdose rates observed in younger demographics, as highlighted in research unveiled at the ANESTHESIOLOGY® 2025 annual conference.
This investigation stands out as one of the pioneering efforts to leverage data from the Centers for Disease Control and Prevention (CDC) in order to spotlight how seniors—frequently overlooked in overdose statistics—are becoming increasingly entangled in the nationwide escalation of deaths involving fentanyl and stimulants. Seniors in this demographic encounter elevated overdose vulnerabilities due to their management of ongoing health conditions, reliance on numerous prescriptions, and the natural slowing of drug metabolism that accompanies advancing age.
Specialists outline the opioid crisis as progressing through four separate phases, each propelled by a distinct substance fueling the fatal overdoses: prescription painkillers dominated the 1990s, heroin gained prominence around 2010, synthetic fentanyl emerged strongly from 2013 onward, and the mixing of fentanyl with stimulants surfaced around 2015.
There is a widespread belief that opioid overdoses predominantly strike younger individuals, noted Gab Pasia, M.A., the primary researcher behind the study and a medical student at the University of Nevada, Reno School of Medicine. Yet, our detailed examination demonstrates that seniors are equally susceptible to fentanyl-associated fatalities, with stimulant combinations becoming far more prevalent in this population. These patterns indicate that older adults are now experiencing the fourth phase of the opioid epidemic in a manner parallel to that of younger groups.
For this analysis, the team reviewed 404,964 death records that cited fentanyl as a contributing factor from 1999 through 2023, drawing from the CDC’s Wide-ranging Online Data for Epidemiologic Research (WONDER) database. Among these, 17,040 cases involved people aged 65 and older, compared to 387,924 instances in adults between 25 and 64 years old.
From 2015 to 2023, the number of fentanyl-related deaths in seniors escalated from 264 to 4,144, representing a 1,470% surge. In younger adults, the figure climbed from 8,513 to 64,694, a 660% rise. Specifically within the senior cohort, fatalities combining fentanyl and stimulants jumped from 8.7% of total fentanyl deaths (23 out of 264) in 2015 to 49.9% (2,070 out of 4,144) in 2023—an extraordinary 9,000% escalation. By contrast, in the younger adult group, such combined deaths increased from 21.3% (1,812 out of 8,513) to 59.3% (38,333 out of 64,694), reflecting a 2,115% growth over the same timeframe.
The researchers selected 2015 and 2023 as focal points because 2015 signaled the onset of the fourth wave of the epidemic, when fentanyl-stimulant deaths among seniors hit their nadir, and 2023 provided the latest available CDC statistics.
Notably, the uptick in fentanyl deaths paired with stimulants among older adults accelerated dramatically starting in 2020, even as fatalities tied to other drugs either stabilized or decreased. Among seniors, cocaine and methamphetamine emerged as the predominant stimulants mixed with fentanyl, outpacing combinations with alcohol, heroin, or benzodiazepines like Xanax and Valium.
Broad national statistics have indicated a climb in fentanyl-stimulant combinations across all adult age brackets, observed Mr. Pasia. Since this was a nationwide, cross-sectional examination, it could only delineate temporal trends without pinpointing causal factors. Nevertheless, the results emphasize that fentanyl overdoses in seniors frequently involve multiple substances rather than fentanyl in isolation, highlighting the critical need to disseminate drug misuse prevention tactics tailored for older patients.
Key Recommendations for Anesthesiologists and Pain Specialists
The study authors recommend that anesthesiologists and pain management professionals take the following steps:
- Understand that the use of multiple substances can affect individuals across every age category, extending beyond just young people.
- Exercise caution in opioid prescriptions for those 65 and older by thoroughly reviewing their medication histories, vigilantly observing patients with prior stimulant use who receive opioids for adverse reactions, and prioritizing non-opioid alternatives where feasible.
- Implement harm-reduction techniques, including training caregivers on naloxone use, streamlining medication regimens, applying straightforward labeling and secure storage guidelines, and ensuring that directives are accessible for those facing memory or visual impairments.
- Conduct comprehensive screenings for older patients regarding diverse substance involvements, not limited to prescribed opioids, to foresee potential issues and refine surgical preparation plans accordingly.
Seniors receiving opioid prescriptions, along with their caregivers, ought to consult their healthcare providers about strategies to prevent overdoses, such as keeping naloxone on hand and recognizing overdose symptoms, advised Richard Wang, M.D., an anesthesiology resident at Rush University Medical Center in Chicago and a co-author of the research. Given these emerging patterns, it has become even more essential to reduce opioid reliance in this at-risk population and explore alternative pain management approaches as suitable. Through thorough patient education and consistent medication list audits, it may be possible to curb this distressing upward trajectory.
